Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
112 results about "Exocytosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Exocytosis (/ˌɛksoʊsaɪˈtoʊsɪs/) is a form of active transport and bulk transport in which a cell transports molecules (e.g., neurotransmitters and proteins) out of the cell (exo- + cytosis) by secreting them through an energy-dependent process. Exocytosis and its counterpart, endocytosis, are used by all cells because most chemical substances important to them are large polar molecules that cannot pass through the hydrophobic portion of the cell membrane by passive means. Exocytosis is in process a large amount of molecules are released thus making it a form of bulk transport.
Bone matrix compositions and methods
Osteoinductive compositions and implants having increased biological activities, and methods for their production, are provided. The biological activities that may be increased include, but are not limited to, bone forming; bone healing; osteoinductive activity, osteogenic activity, chondrogenic activity, wound healing activity, neurogenic activity, contraction-inducing activity, mitosisinducing activity, differentiation-inducing activity, chemotactic activity, angiogenic or vasculogenic activity, and exocytosis or endocytosis-inducing activity. In one embodiment, a method for producing an osteoinductive composition comprises providing partially demineralized bone, treating the partially demineralized bone to disrupt the collagen structure of the bone, and optionally providing a tissue-derived extract and adding the tissue-derived extract to the partially demineralized bone. In another embodiment, an implantable osteoinductive and osteoconductive composition comprises partially demineralized bone, wherein the collagen structure of the bone has been disrupted, and, optionally, a tissue-derived extract.
Owner:WARSAW ORTHOPEDIC INC
Bone matrix compositions and methods
Owner:WARSAW ORTHOPEDIC INC
Neuronal exocytosis inhibiting peptides
ActiveUS20100021510A1The process is simple and effectiveCosmetic preparationsPowder deliveryArylExocytosis
The invention relates to peptides of general formula (I):R1-AA-R2 (I)which can regulate neuronal exocytosis, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or pharmaceutically acceptable salts thereof, wherein AA is a sequence of 3 to 40 adjacent amino acids contained in the amino acid sequence of the SNAP-25 protein, R1 is selected from the group consisting of H or alkyl, aryl, aralkyl or acyl group; and R2 is selected from the group consisting of amino, hydroxyl or thiol, substituted or non-substituted with aliphatic or cyclic groups, with the condition that when R1 is H or acetyl, R2 is not non-substituted amino, hydroxyl or thiol. The invention also relates to a method of obtaining such peptides, cosmetic or pharmaceutical compositions containing them and their use to treat those conditions requiring neuronal exocytosis regulation, preferably for treating the skin.
Owner:BCN PEPTIDES SA
Neurotrophic factor production promoting device
ActiveUS20090326315A1Easy to produceElectrotherapyMagnetotherapy using coils/electromagnetsDiseaseExocytosis
A neurotrophic factor production promoting device is provided, which is able to promote production of a neurotrophic factor or neurotrophic factor-like substance in an affected area by a simple technique that, regardless of the place of treatment, can be performed without transplantation of cells or injection into the affected area, in order to prevent or treat various diseases such as brain diseases. In order to apply a high frequency alternating magnetic field in the range of 20 MHz to 180 MHz, 280 MHz to 600 MHz, or 700 MHz to 1000 MHz to cells at a magnetic flux density of no more than 0.01 Tesla, the neurotrophic factor production promoting device includes a high frequency electromagnetic wave generating means generating a high frequency electromagnetic wave of the abovementioned frequency, in which the magnetic stimulation by the high frequency alternating electromagnetic field of the abovementioned high frequency allows the intracellular concentration of calcium ions to be increased so that exocytosis of the neurotrophic factor group is induced, and the magnetic stimulation allows messenger ribonucleic acid (mRNA) of the neurotrophic factor group to be increased in the cells so that the synthesis and extracellular release of the neurotrophic factor group are promoted.
Owner:P MIND
Exosome-encapsulated nano drug-loading system for tumor treatment and preparation thereof
ActiveCN108543074AIngestion behaviorExcellent killing effectOrganic active ingredientsInorganic non-active ingredientsExocytosisTumor targeting
The invention discloses an exosome-encapsulated nano drug-loading system for tumor treatment, and preparation thereof. The system is obtained by utilizing cell endocytosis of a drug-loading nanometermaterial and then exocytosis. The drug-loading nanometer material is loaded with an antitumor medicine including at least one of a chemotherapeutic, a medicine used for immunotherapy and a medicine used for modifying a tumor microenvironment. The composition, structure and the like of the key outer component biofilm encapsulating the nano drug-loading system are improved, and compared with the prior art, the exosome-encapsulated nano drug-loading system provides a novel route for biofilm-based biological processed nanoparticles. By utilization of the exosome-encapsulated nano drug-loading system, the composition and the structure of the exosome can be maintained greatly, and the obtained exosome-encapsulated nano drug-loading system has good stability and tumor targeting performance duringblood circulation. .
Owner:HUAZHONG UNIV OF SCI & TECH
Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
InactiveUS20060134103A1Simple processIncrease ratingsSenses disorderPeptide/protein ingredientsExocytosisActive agent
Disclosed herein are multimeric molecular complexes and compounds that are multivalent, i.e., they have two or more targeting elements directed to a ligand that confers paracellular transporting properties and / or transcytotic properties to complexes and compounds to which it is bound. The complexes and compounds have properties that are different from the properties of monomers, complexes and compounds having only one targeting element directed to a paracellular and / or transcytotic ligand. The complexes and compounds of the invention undergo endocytosis, transcytosis and exocytosis; following endocytosis, the complexes or compounds may be transported into the cytosol or an organelle of a cell. In polarized cells, transcytosis can proceed in a “forward” or “reverse” direction. Reverse transcytosis is used for the non-invasive delivery of biologically active agents from the lumen of, e.g., the gastrointestinal tract or the airways of lungs, to the circulatory system. The complexes and compounds are incorporated in various compositions and medical devices suitable for medicinal or veterinary use.
Owner:HAWLEY STEPHEN +4
Functional albumin and preparation method of nano preparation of functional albumin
ActiveCN105288647AThe synthesis method is simpleChange isoelectric point to basicPowder deliveryOvalbuminExocytosisDrug release
The invention discloses functional albumin and a preparation method of a nano preparation of the functional albumin. The nano preparation of the functional albumin consists of the functional albumin, metal ions and a drug; the metal ions can simultaneously form coordination bonds with the functional albumin and the drug, and can form nanoparticles through induced self-assembly. The nano preparation, through an endocytosis mediated by an albumin receptor (SPARC) on the surface of tumor cells, can deliver the drug into the drug-resistant tumor cells, so as to effectively avoid the exocytosis effect of a p-gp pump on the drug, and then as the coordination bonds break in an acid tumor cell environment through a pH responsibility, the drug releases in cytoplast, enters cell nucleus and inlays in DNA so as to inhibit the synthesis of nucleic acid; and therefore, the growth of the tumor cells is inhibited. Through in vitro characterization, the nano preparation can achieve the relatively good pH responsibility; and through activity evaluation on a cellular level, the system is capable of effectively delivering the drug into the cells, so as to achieve relatively good pH responsive release.
Owner:CHINA PHARM UNIV
Production of cultured human mast cells and basophils for high throughput small molecule drug discovery
InactiveUS7070996B2BiocideMicrobiological testing/measurementProgenitorHigh-Throughput Screening Methods
Provided are methods for producing and screening proliferated populations of CD34-negative progenitor cells, mucosal mast cells, connective tissue-type mast cells and basophil cells. The methods generate uniform proliferated populations of cells. The proliferated populations contain a uniform population of a size suitable for use in high throughput screening methods, for example, screening for agents that alter exocytosis. The invention includes screening the proliferated populations with at least one candidate bioactive agent, and evaluating the cells to detect a cell with an altered phenotype. The invention also includes isolating a candidate bioactive agent that causes the altered phenotype. Additionally, cells formed according to the described methods are also encompassed by the invention.
Owner:RIGEL PHARMA
Method of inhibiting leukocytes with human cxc chemokine receptor 3 antibody
InactiveUS20100061983A1Sugar derivativesPeptide/protein ingredientsExocytosisAntiendomysial antibodies
The present invention relates to proteins or polypeptides, referred to herein as isolated and / Or recombinant mammalian (e.g., human) IP-10 / Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and / or Mig), and / or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.
Owner:THEODOR KOCHER INST +1
Bone Matrix Compositions and Methods
Owner:WARSAW ORTHOPEDIC INC
Alkaline pectic enzyme producing engineering strain and its construction and method for producing alkaline pectic enzyme with the same
InactiveCN101157900ASimple purification processReduce typesFungiMicroorganism based processesPectinaseExocytosis
An engineering bacterium of producing alkaline pectinase, a construction thereof and a method of producing alkaline pectinase by using the alkaline pertain to the technical field of bioengineering. The invention uses nonpathogenic bacillus sp WSHB04-02 genes group as a model and adopts amplification technology of PCR. And then the sequence pel containing 1.2kb coding alkaline pectinase genes section is obtained. At the same time from the point of the demand for industrial production, the invention makes use of a shuttle expression carrier to restructure yeast Pichiapastoris(pel), which means to produce engineering bacterium CGMCC No.2143 of alkaline pectinase (E.C.4.2.2.2). The invention also provides CGMCC No.2143 as the method of producing alkaline pectinase for fermented yeast strain. The genes engineering bacterium aims at exocytosis of protein and the species of extracellular protein is few, which simplifies the purification technique of producing alkaline pectinase by using microorganism and reduces the cost and shoetens the time for ferment. Besides, the invention improves the production efficiency and lays a foundation for industrialization of the ferment method of producing alkaline pectinase by using microorganism.
Owner:JIANGNAN UNIV
Method of inhibiting leukocytes with human CXC chemokine receptor 3 antibody
The present invention relates to proteins or polypeptides, referred to herein as isolated and / or recombinant mammalian (e.g., human) IP-10 / Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and / or Mig), and / or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.
Owner:MILLENNIUM PHARMA INC +1
Use of deleucocytation filters for defensin purification
The invention concerns the use of deleucocytation filters for defensin purification. More precisely, the invention concerns a method for purifying defensins, including the following steps: passing a blood sample on a deleucocytation filter; detaching the cells retained on the deleucocytation filter, inducing exocytosis of the defensins by those cells.
Owner:ESTAB FR DU SANG
Targeting carbon nanotube drug delivery system, and preparation method and applications thereof
ActiveCN106552268AIncrease intakeLong retention timeOrganic active ingredientsPharmaceutical non-active ingredientsSolubilityExocytosis
The invention provides a targeting carbon nanotube drug delivery system, and a preparation method and applications thereof. The drug delivery system comprises a conjugate and a drug carrying carbon nanotube that is combined with the conjugate in a non-covalent mode; wherein the conjugate comprises a modifying material that can enhance the water solubility and biocompatibility of the drug delivery system and a targeting molecule that is combined with the modifying material in a covalent mode; and the drug carrying carbon nanotube is composed of carbon nanotubes and drug molecules that adsorb on the surface of the carbon nanotubes. One step modification technology is adopted, the problems on purification and yield caused by multi-step modification are avoided; at the same time, the carbon nanotube and drug delivery system are enable to have water solubility, biocompatibility, and multi-functions; the exocytosis of drug resistant tumor cells on drug molecules is effectively overcome, a novel strategy is provided for overcoming multi-drug resistance of tumor cells, and thus the provided drug delivery system has a wide application prospect in the field of drug resistant tumor treatment.
Owner:INST OF PHARMACOLOGY & TOXICOLOGY ACAD OF MILITARY MEDICAL SCI P L A
Fusarium fujikuroi mutant strain bred through ARTP mutagenesis technique and application
The invention relates to a fusarium fujikuroi mutant strain- fusarium fujikuroi GA-347 ( Fusarium fujikuroi GA-347 ) bred through an ARTP mutagenesis technique and an application of the fusarium fujikuroi mutant strain. The strain can be applied to industrial production in a large scale. The strain is preserved in China Center for Type Culture Collection, the address is Wuhan University, the postcode is 430072, the preservation No. is CCTCC NO:M 2019378, and the preservation date is 20 May 2019. In the growth process of the strain, conidium is not generated, the strain is inoculated to a liquid seed culture medium, and after cells grow to be mature, the cells are switched to a fermentation culture medium, so that the fermentation level is greatly increased, and the yield of gibberellin achieves 22 times of that of wild bacteria and leads in the national level. The gibberellin is in exocytosis, can be totally obtained from fermentation liquid, solid-liquid separation is facilitated, andthe extraction yield is increased. Besides, the utilization rate of equipment of raw materials is increased, the production cost is greatly reduced, and the strain has obvious economic benefits and social benefits.
Owner:ZHEJIANG UNIV OF TECH
Method for optimizing signal peptide and improving exocytosis expression of trypsin
ActiveCN104312933AIncrease productionGood yieldFungiMicroorganism based processesPichia pastorisExocytosis
The invention discloses a method for optimizing a signal peptide and improving exocytosis expression of trypsin, belonging to the technical field of genetic engineering. The signal peptide is fused with trypsin to express 8 types of pichia pastoris exocytosis signal peptides, and a starter (pAOX) is induced by methanol to express regrouped trypsin on pichia pastoris GS115 chromosome. Compared with the original alpha-factor signal peptide, the enzyme activity of the trypsin of the alpha mf signal peptide is improved by 2.75 times, and the problem that the exocytosis amount of the trypsin is low can be solved. By utilizing the method to produce the trypsin, the yield is high, the process is simplified, and the industrial application is convenient to realize.
Owner:JIANGNAN UNIV
Gene knockout Escherichia coli beneficial to recombinant protein exocytosis and application thereof
InactiveCN104845926AIncrease extracellular secretionImprove permeabilityBacteriaHydrolasesEscherichia coliExocytosis
The invention provides a gene knockout Escherichia coli beneficial to recombinant protein exocytosis and application thereof, relating to the field of modification of Escherichia coli genetic group genes. The gene knockout Escherichia coli beneficial to recombinant protein exocytosis is prepared by knocking out lipopolysaccharide synthesis related genes in Escherichia coli. The invention also provides a construction method of the gene knockout Escherichia coli and application of the gene knockout Escherichia coli in preparing extracellular soluble proteins. The preparation method is simple, and has the advantages of high efficiency and low cost. After the lipopolysaccharide-synthesized related genes are knocked out, the permeability of the pericellular membrane is enhanced, thereby obviously enhancing the recombinant protein exocytosis.
Owner:NANJING UNIV OF TECH
Compounds which inhibit neuronal exocytosis
Compounds of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Yp—Zq—R2, their stereoisomers, mixtures thereof and / or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and / or prevention of pain, inflammation, itching, neurological, compulsive and / or neuropsychiatric diseases and / or disorders and in processes of treatment and / or care of the skin, hair and / or mucous membranes mediated by neuronal exocytosis.
Owner:LUBRIZOL ADVANCED MATERIALS INC
Production of cultured human mast cells and basophils for high throughput small molecule drug discovery
Provided are methods for producing and screening proliferated populations of CD34-negative progenitor cells, mucosal mast cells, connective tissue-type mast cells and basophil cells. The methods generate uniform proliferated populations of cells. The proliferated populations contain a uniform population of a size suitable for use in high throughput screening methods, for example, screening for agents that alter exocytosis. The invention includes screening the proliferated populations with at least one candidate bioactive agent, and evaluating the cells to detect a cell with an altered phenotype. The invention also includes isolating a candidate bioactive agent that causes the altered phenotype. Additionally, cells formed according to the described methods are also encompassed by the invention.
Owner:RIGEL PHARMA
Compounds which inhibit neuronal exocytosis
Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and / or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and / or prevention of pain, inflammation, itching, neurological, compulsive and / or neuropsychiatric diseases and / or disorders and in processes of treatment and / or care of the skin, hair and / or mucous membranes mediated by neuronal exocytosis.
Owner:LUBRIZOL ADVANCED MATERIALS INC
Monoacyl-diacyl lipase, and coding gene and application thereof
Owner:CHINA AGRI UNIV
Neurotrophic factor production promoting device
ActiveUS8562506B2Easy to produceElectrotherapyMagnetotherapy using coils/electromagnetsDiseaseExocytosis
Owner:P MIND
Hybrid molecules and their use for optically detecting changes in cellular microenvironments
The invention relates to methods and compositions which utilize the emission of light to monitor changes in microenvironments involving cells. The invention is especially useful for monitoring exocytotic activity such as detecting quantal release of synaptic vesicles. Fusion proteins of Cypridina luciferase and synaptotagmin-I or VAMP / synaptobrevin-2 were targeted to synaptic vesicles and, upon exocytosis, formed light-emitting complexes with luciferin present in the extracellular medium. Photon emissions in the presence of a depolarizing stimulus can be observed with these systems. pH-sensitive mutants of green fluorescent protein are also provided, which are useful for visualizing exocytosis and for imaging and measuring the pH of intracellular compartments.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT
Positioning mutant gene of Trichoderma viride endoglucanase and application thereof
The invention relates to the field of gene engineering, and specially relates to a positioning mutant gene of Trichoderma viride endoglucanase, wherein the nucleotide sequence of the mutant gene is shown in SEQ ID NO : 3. The Trichoderma viride endoglucanase gene is subjected to a site-directed mutagenesis to get the positioning mutant gene of the Trichoderma viride endoglucanase, named as EG-mut and having a nucleotide sequence shown in SEQ ID NO : 3. Pichia yeast secretory-type expression vectors pPIC9K-EG and pPIC9K-EG-mut are constructed respectively by using the Trichoderma viride endoglucanase gene (EG) and the positioning mutant gene of Trichoderma viride endoglucanase (EG-mut) and are respectively transformed into the pichia yeasts to get recombinant pichia yeasts which are induced to express, and the enzyme activities are determined. The result shows that the enzyme activity of exocytosis endoglucanase of the recombinant pichia yeast strain with the mutant sequence EG-mut is increased by 15.27% compared with that of recombinant pichia yeast strain with the original sequence EG.
Owner:林忠平
Construction method of corynebacterium glutamicum engineering bacteria for high production of L-lysine
PendingCN105950524AReduce contentDecreased extracellular secretionBacteriaStable introduction of DNACorynebacterium efficiensHigh concentration
The invention relates to a construction method of corynebacterium glutamicum engineering bacteria for high production of L-lysine. According to the method, the engineering bacteria are constructed by inactivating an NCgl1221 gene of corynebacterium glutamicum, wherein the nucleotide sequence of an NCgl1221 gene encoding frame is shown as SEQ ID NO. 1. The invention provides a construction method of a corynebacterium glutamicum strain for high production of the L-lysine; the constructed strain can obviously decrease glutamicum exocytosis due to the inactivation of the endogenous gene NCgl1221; compared with a wild strain, the strain can be used for producing high-concentration L-lysine and can effectively reduce the content of glutamicum which is a byproduct of a fermentation liquor; and the strain, as an L-lysine production strain, can further reduce production cost and purification cost.
Owner:QILU UNIV OF TECH +2
Method for improving exocytosis level of recombinant protein of escherichia coli based on dacA
The invention discloses a method for improving the exocytosis level of a recombinant protein of escherichia coli based on dacA, relating to the fields of gene engineering and fermentation engineering. By virtue of overexpression of a D-alanyl-D-alanine carboxypeptidase gene, the recombinant escherichia coli with the recombinant protein with the exocytosis level in overexpression is obtained. By virtue of the method, the secretion capacity of the recombinant protein of the escherichia coli can be remarkably improved. By utilizing amylase as a mode recombinant protein, the content of extracellular recombinant amylase of the escherichia coli is increased from 8.54% of a control group to 51.77%. The method has important guiding significance to the efficient secretion and production of the recombinant protein in the escherichia coli.
Owner:JIANGNAN UNIV
Multiparameter FACS assays to detect alterations in exocytosis
Described is a method for screening for alterations in exocytosis of a population of cells. The cells are sorted by a FACS machine by assaying for alterations in at least three of the properties selected from the group consisting of light scattering, fluorescent dye uptake, fluorescent dye release, annexin granule binding, surface granule enzyme activity, and the quantity of granule specific proteins. Methods for screening for bioactive agents capable of modulating exocytosis in a cell are also described. The methods provide for reduced background and increased specificity without increasing the time or steps involved in assaying for exocytosis.
Owner:RIGEL
Method for overcoming reverse tolerance of tumors
ActiveCN110755457AAddressing technical issues of drug resistanceOvercome drug resistanceOrganic active ingredientsMicrobiological testing/measurementExocytosisCancer cell
The invention discloses a new function of cyanobacteria. Under irradiation of specific wave length lasers, and through photosynthesis, oxygen is generated, the condition of oxygen deficiency caused bytumors can be improved, and the problem of reverse tolerance of chemicals, such as adriamycin can be effectively solved. The cyanobacteria is subjected to photosynthesis in light to generate oxygen,and under the aerobic condition, hypoxia factors are reduced for tumor cells, so that multidrug resistance genes can be restrained, expression of P-glycoprotein is restrained to restrain exocytosis ofcancer cells on adriamycin, the reverse tolerance of the cancer cells on the reverse tolerance is overcome, and the antitumor treatment effect can be increased.
Owner:SHENZHEN INST OF ADVANCED TECH
Methods and compounds for the treatment of mucus hypersecretion
InactiveUS20080152667A1Effective treatmentPrevent hypersecretionBacterial antigen ingredientsNervous disorderExocytosisMedicine
Owner:HEALTH PROTECTION AGENCY
Novel ultrasensitive cell based sensors and uses thereof
ActiveUS20130203078A1Increases magnitudeEnhanced interactionMicrobiological testing/measurementFermentationHigh resistanceHeterologous
The present invention relates to a novel cell based sensor useful for drug discovery that comprises a cell line with professional regulated exocytosis of secretory granules transfected with a protease as a reporter polypeptide stored in the regulated secretory granules of the cell line with professional regulated exocytosis and having either an endogenous or a heterologous molecule as a modulator of regulated secretory granules exocytosis, such said granule stored protease reporter having at least: a high resistance to conditions already present inside the granules such as low pH and proteolysis by other proteases; enzymatic activity after exocytosis; a highly specific cleavage sequence; a very low level of secretion under unstimulated or basal conditions; and a high signal to background activity in a media compatible with cell culture viability and granule exocytosis for a high throughput robust and sensitive detection.
Owner:CANVAX BIOTECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com